Neutrophils from patients with myelodysplastic syndrome (MDS) show a disturbed differentiation pattern and are generally dysfunctional. To study these defects in more detail we investigated the reactive oxygen species (ROS) production and F-actin polymerisation in neutrophils from MDS patients and healthy controls, and the involvement of N-formyl-L-metionyl-L-lucyl-Lphenylalanine (fMLP) and granulocyte macrophage-colony-stimulating factor (GM-CSF)-stimulated signal transduction pathways. Following fMLP stimulation, similar levels of respiratory burst, F-actin polymerisation and activation of the small GTPase Rac2 were demonstrated in MDS and normal neutrophils. However, GM-CSF and G-CSF priming of ROS production were significantly decreased in MDS patients. We subsequently investigated the signal transduction pathways involved in ROS generation, and demonstrated that fMLPstimulated ROS production was inhibited by the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the MAP/ERK kinase (MEK) inhibitor U0126. In contrast, ROS production induced by fMLP stimulation of GM-CSFprimed cells was inhibited by both LY294002 and U0126. This coincides with an enhanced protein kinase B (PKB/Akt) phosphorylation that was PI3K dependent and enhanced extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) phosphorylation that was PI3K independent. We demonstrated higher protein levels of the PI3K subunit p110 in neutrophils from MDS patients and found that though the fMLP-induced phosphorylation of PKB/Akt and ERK1/2 could also be enhanced by pre-treatment with GM-CSF in these patients, the degree and kinetics of PKB/Akt and ERK1/2 phosphorylation were significantly disturbed. These defects were observed despite a normal GM-CSF-induced signal transducer and activator of transcription 5 (STAT5) phosphorylation. Our results indicate that the reduced priming of neutrophil ROS production in MDS patients might be caused by a disturbed convergence of the fMLP and GM-CSF signalling routes.
Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia Introduction
The Myelodysplastic syndromes (MDS) are characterised by a differentiation defect in the multipotent stem cell compartment, resulting in a disturbed proliferation and differentiation of the erythroid, myeloid or megakaryocytic lineage 1 . With regard to the myeloid lineage it has been shown that the intrinsic defect leads to granulocytopenia and to aberrant functioning of neutrophils. For instance, there have been reports indicating that reorganisation of the actin cytoskeleton 2 and the production of reactive oxygen species (ROS) 3;4 are affected in neutrophils from MDS patients. Bacterial infections are the most common cause of death in MDS patients 5 . The capacity of neutrophils to produce ROS such as O 2 -and H 2 O 2 during the respiratory burst is essential for their bactericidal activity 6 . ROS production can be stimulated by chemotactic factors, such as the bacterial peptide analogue N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) 7 .
Proinflammatory agents like granulocyte-macrophage-colony stimulating factor (GM-CSF) or granulocyte-colony-stimulating factor (G-CSF) prime the fMLPmediated respiratory burst, but do not elicit ROS production on their own 8;9 . This priming effect is not specific for ROS production but has also been described for other cellular events, such as degranulation, migration and adherence 10;11 .
The respiratory burst and additional neutrophil effector functions such as granule trafficking and phagocytosis are dependent on the organisation of the actin cytoskeleton [12] [13] [14] [15] . There are 2 forms of actin, a monomeric form (G-actin) and a filamentous form (F-actin), that exist in an equilibrium in the cell. Upon stimulation of neutrophils with chemotactic factors, rapid conversion of G-actin to F-actin occurs 16;17 . In contrast to ROS production, F-actin polymerisation cannot be primed by proinflammatory factors. Different signal transduction pathways have been identified that are critical for the cellular functions of neutrophils. Rac2, a member of the Rho family of small GTPases, acts as a molecular switch by cycling between an inactive guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. Rac2 is involved in the reorganisation of the actin cytoskeleton [18] [19] [20] and the fMLP mediated respiratory burst, as demonstrated by experiments in Rac -/-mice and in patients with an inhibitory Rac2 mutation [21] [22] [23] [24] .
In addition, phosphatidylinositol 3 kinase (PI3K) plays an important role in neutrophil ROS production. Several class I isoforms of PI3K have been identified; class I A catalytic subunits p110α, β and δ associate with the regulatory subunit p85, whereas the class I B catalytic subunit p110γ associates with p101. Evidence for PI3K involvement in neutrophil respiratory burst comes from studies with specific PI3K inhibitors [25] [26] [27] . Furthermore, lipid products of PI3K associate with the phagocyte oxidase proteins p47 phox and p40 phox , two components of the neutrophil oxidase complex. The association of one of these lipids with p40 phox has a regulatory effect on ROS production 28;29 . Additional studies have revealed that the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2), a key member of the mitogen-activated protein kinase (MAPK) cascade, might be involved in the neutrophil respiratory burst. Inhibition of ERK activation by chemical inhibitors resulted in a reduction of fMLP-induced and GM-CSF-primed ROS production in human neutrophils in several studies 27;30 .
In this study, we further characterised the disturbed neutrophil responses in MDS and questioned which signal transduction pathways might be involved in aberrant neutrophil functioning. We demonstrated normal fMLP-mediated respiratory burst, F-actin polymerisation and Rac2 activation in neutrophils from MDS patients but found a strongly decreased priming effect of GM-CSF and G-CSF on ROS production. Analysis of signal transduction pathways revealed higher protein expression levels of the PI3K subunit p110 in neutrophils from MDS patients. Further examination also indicated altered phosphorylation levels of protein kinase B (PKB/Akt) and ERK1/2 in MDS patients.
Materials and methods
Reagents N-formyl-L-methionyl-L-leucyl-L-Phenylalanine (fMLP), phorbol 12-myristate 13-acetate (PMA), ferricytochrome c and superoxide dismutase (SOD) were obtained from Sigma (St. Louis, MO). Recombinant human GM-CSF was from Sandoz (Uden, The Netherlands) and r-metHuG-CSF was from Roche (Almere, The Netherlands). The PI3K inhibitor LY294002 was purchased from Alexis (Läufelfingen, Switzerland) and the MEK inhibitor U0126 was obtained from New England Biolabs (Beverly, MA). The GST-PAK-CD construct was a generous gift from Dr. P. J. Coffer. Oregon Green 514-phalloidin and Dihydro-rhodamine 123 (DHR123) were purchased from Molecular Probes (Eugene, OR). Polyclonal antibody against ERK1/2 (K23), and monoclonal antibody against PI3-kinase p110 (D-4) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody against phosphorylated STAT5A/B (Y694/Y699) was from Upstate Biotechnology (Lake Placid, NY), antibodies against phosphorylated ERK1/2 (Thr202/Tyr204) and phosphorylated PKB/Akt (Ser473) were obtained from Cell Signaling technology (Beverly, MA). Anti-Rac antibody was from Transduction Laboratories (Lexington, KY).
Patients
Fourteen patients with MDS were studied. MDS was classified as refractory anemia (RA) or RA with ringed sideroblasts (RARS) according to FAB cooperative group criteria 31 . Informed consent was obtained from all patients. The protocol was approved by the Human Subject Review Board of the University Hospital Groningen.
Isolation of neutrophils
Peripheral blood, anti-coagulated with 0.32% sodium citrate, was obtained from healthy volunteers and MDS patients. Neutrophils were isolated as described by Koenderman et al 32 . In short, mononuclear cells were removed by centrifugation over Fycoll-Paque (Amersham, Upsala, Sweden) and erythrocytes were lysed with ice-cold NH 4 Cl solution. Neutrophils were allowed to recover for 30 min at 37 °C in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented with 0.5% human serum albumin (HSA; CLB, Amsterdam, The Netherlands). Before stimulation, cells were resuspended in incubation buffer (20 mM HEPES, 132 mM NaCl, 6 mM KCl, 1 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 5 mM glucose, 1 mM CaCl 2 , 0.5% HSA). In all cases, the cell population isolated consisted of >95% neutrophils as determined by May-Grünwald Giemsa staining.
F-actin polymerisation assay F-actin polymerisation was measured as described by Nijhuis et al 33 . In short, neutrophils (2.5 x 10 6 cells/mL) were stimulated with 1 µM fMLP. At indicated time points, cells were fixed and permeabilised for 10 min at room temperature with ice-cold 3% formaldehyde in PBS, containing 100 µg/mL lysophosphatidylcholine (Sigma, St.Louis, MO). Polymerised F-actin was stained with 2.5 U/mL Oregon Green 514-phalloidin for 30 minutes at room temperature. The intracellular fluorescence was determined by flow cytometry (FACScalibur, Becton Dickinson Medical Systems, Sharon, MA). , did not show differences in the amount of total PKB/Akt protein (data not shown). Quantification of phosphorylation levels was performed by densitometry of the films, using ImageMaster1D Elite (Pharmacia, Woerden, the Netherlands).
Respiratory burst measurement

Statistical analysis
For respiratory burst measurements, differences in experimental values between healthy controls and MDS patients were calculated using the Mann-Whitney U test. Differences between paired samples were calculated using the Wilcoxon nonparametric test or the Student t test for samples treated with signal transduction inhibitors. For comparison of PI3K p110 levels in MDS patients and healthy donors, densitometry values of p110 protein were corrected for the amount of ERK protein present in the samples, and differences between the normalised values were calculated using the Student t test for unpaired samples. For quantification of phospho-PKB/Akt and phospho-ERK1/2 blots, differences in densitometry values of healthy controls as a percentage of that of MDS patients were calculated using the Student t test for paired samples. Data were expressed as mean ± SEM. P values <0.05 were considered significant.
Results
FMLP stimulated F-actin polymerisation and Rac2 activation are not disturbed in neutrophils from MDS patients
The fMLP-induced F-actin polymerisation was examined in neutrophils and compared in neutrophils from MDS patients and healthy controls (n = 8 for each group). On stimulation of neutrophils with 1 µM fMLP, a transient increase in the relative amount of F-actin was observed, that was maximal within 30 seconds and declined after 2 to 5 minutes. The maximum relative increase of F-actin content in neutrophils from healthy subjects was 507 ± 22%. This was comparable to the maximum relative increase of F-actin in neutrophils from MDS patients (507 ± 52%; p=0.963), though in MDS patients there was a wider variation in relative F-actin increase. The kinetics of F-actin polymerisation in MDS neutrophils was similar to that of healthy volunteers (data not shown).
Although patients and healthy controls showed no significant difference in the kinetics and relative amount of F-actin formed in response to fMLP, 3 MDS patients did have a subpopulation of neutrophils (21, 48 and 49% of the total population) that had virtually no detectable F-actin polymerisation ( Figure 1 ). These subpopulations could not be distinguished from the responsive neutrophil populations in dot-plot profiles, because their scattering profiles were identical. To confirm the normal fMLP response of MDS neutrophils at the molecular level, the fMLP-stimulated Rac2 activation was studied by using a GST-beads pulldown technique. Figure 2A demonstrates that maximal Rac2 activation in neutrophils from healthy subjects was achieved after 15 seconds of fMLP stimulation and declined to near baseline levels within 15 minutes. Similar results were obtained in neutrophils from MDS patients (n = 8) though there was some variation in the extent and time course of Rac2 activation among donors ( Figure  2B ). The mean increase in Rac2 activation after 15 seconds of fMLP stimulation was 729 ± 202% in neutrophils from healthy donors (n = 8), versus 658 ± 179% in neutrophils from MDS patients, as determined by densitometry of the films (p=0.795, data not shown). Western blot analysis of whole cell lysates of neutrophils from 5 MDS patients and 3 healthy controls, run on one gel, demonstrated equal amounts of total Rac protein present in all individuals (data not shown).
Priming of the respiratory burst leads to an enhancement of superoxide radical production that is higher in healthy controls than in MDS patients
Given that the production of ROS is an essential antibacterial defence mechanism of neutrophils, we studied the amount of superoxide produced in neutrophils in response to fMLP and the enhancement of this response by priming with GM-CSF, G-CSF, or both. H 2 O 2 production was calculated by expressing the fluorescence of rhodamine 123 in stimulated cells as a percentage of the fluorescence of unstimulated cells. Stimulation was stopped by the addition of 3 X Lysis Buffer. Activated Rac2 was precipitated using GST-PAKcrib protein precoupled to glutathione-Sepharose beads. Proteins were separated by 15% SDS-PAGE and membranes were probed with Rac antibodies, followed by enhanced chemiluminescence. Rac activation was investigated in neutrophils from 8 MDS patients and 8 healthy controls. (A) Two representative blots from healthy subjects. (B) Three representative blots from MDS patients. Equal amounts of glutathione-Sepharose beads were loaded in all samples, as determined by Ponceau S staining of the membranes (not shown).
As shown in Figure 3A , fMLP stimulation induced the production of ROS to a similar level in neutrophils from healthy controls and MDS patients (196 ± 18% and 257 ± 48%, respectively; p=0.753). In neutrophils from healthy donors, stimulation with GM-CSF or G-CSF alone did not lead to H 2 O 2 production (data not shown). However, priming of the neutrophils with GM-CSF or G-CSF or both followed by fMLP stimulation lead to a significantly higher respiratory burst (656 ± 65%, 329 ± 44% and 646 ± 60%, respectively) than when cells were stimulated with fMLP alone (p=0.012 for all 3 groups). In neutrophils from MDS patients, the mean percentage increase in fluorescence intensity stimulated by 1 µM fMLP following GM-CSF or G-CSF priming were 323 ± 39% and 276 ± 50%, respectively, which was significantly higher than fMLP stimulation alone (p=0.017 and 0.018, respectively). However, as shown in Figure 3B , the percentage increase in H 2 O 2 production because of priming of neutrophils with GM-CSF, G-CSF or both was significantly decreased in neutrophils from MDS patients Figure 3 . Priming of fMLP-stimulated H2O2 production by GM-CSF and G-CSF is significantly decreased in neutrophils from MDS patients compared with healthy subjects. Neutrophils were stimulated for 30 minutes with 1 µM fMLP with or without preincubation for 15 minutes with 5 ng/mL GM-CSF, 2.5 ng/mL G-CSF or both. The production of H2O2 after stimulation was measured by FACS analysis and expressed as a percentage of the fluorescence in unstimulated cells. (A) Mean ROS production was calculated for 8 healthy subject and 8 MDS patients. Asterisks represent significant differences in percentage H2O2 production in the primed groups versus the groups that were stimulated with fMLP alone (P < 0.05). (B) The respiratory burst enhancing capabilities of GM-CSF, G-CSF, or both were calculated for each individual donor as follows; (GM-CSF + fMLP)/fMLP, (G-CSF + fMLP)/fMLP and (GM-CSF + G-CSF + fMLP)/fMLP. The mean priming capacity of GM-CSF, G-CSF or both on neutrophil respiratory burst are shown for 8 healthy subjects and 8 MDS patients. Differences between MDS patients and healthy controls were calculated using the Wilcoxon nonparametric tests. (* P < 0.05).
compared to healthy controls (p=0.002, p=0.012 and p=0.003 respectively). These results indicate that whereas the fMLP triggered H 2 O 2 production is normal in MDS patients, GM-CSF and G-CSF priming of the respiratory burst are considerably disturbed. These results were confirmed for O 2 -production by measuring ferricytochrome c reduction in the presence and absence of superoxide dismutase. Figure 4A shows that there was no significant difference in O 2 -production in response to fMLP stimulation in neutrophils from healthy donors (n=3) and MDS patients (n=4). When neutrophils were primed with GM-CSF, subsequent fMLP stimulation triggered significantly higher O 2 -generation in neutrophils from healthy donors then in MDS patients ( Figure 4B ). In contrast, stimulation of O 2 -production by PMA, which is much slower in onset, was equal in neutrophils from MDS patients and healthy donors ( Figure 4C ). These results indicate that priming of the generation of multiple ROS is greatly disturbed in neutrophils from MDS patients.
expressed as the difference in OD550 nm (∆OD 550) between the ferricitochrome c reduction test in the absence and in the presence of 13.16 U/mL SOD. Each test was performed in quadruplicate. The mean O2-production for 3 healthy volunteers and 4 MDS patients are shown. Differences between MDS patients and healthy controls were calculated using the Wilcoxon nonparametric test. (* P < 0.05). stimulated with 1 µM fMLP, (B) primed with 5 ng/mL GM-CSF for 15 min before fMLP stimulation or (C) stimulated with 100 ng/mL PMA, and plates were scanned repetitively at 550 nm using an automated microplate reader. Superoxide production was PI3K is involved in fMLP-and GM-CSF-stimulated respiratory burst and PKB/Akt phosphorylation in neutrophils from healthy donors
Our studies indicate that the priming effect of GM-CSF and G-CSF on the fMLPinduced respiratory burst is disturbed in MDS. To elucidate the signal transduction routes involved in the ROS production in healthy neutrophils, several chemical inhibitors of signal transduction pathways were used. First, we tested the effect of the specific PI3K inhibitor, LY294002, on the fMLP-stimulated respiratory burst in neutrophils, with or without GM-CSF pretreatment. Figure 5A demonstrates that the fMLP-induced respiratory burst could be significantly inhibited at a concentration of 1 µM LY294002 (32 ± 8%; p=0.021). Higher concentrations of LY294002 lead to an even more pronounced reduction in fMLP-stimulated ROS production (66 ± 5% and 85 ± 8% for 10 and 100 µM LY294002, respectively; p<0.05). The GM-CSF-primed respiratory burst was also significantly attenuated by preincubation of neutrophils with all concentrations LY294002 tested. At concentrations of 1 and 10 µM LY294002, the reduction in fMLP-stimulated ROS production was significantly higher in the GM-CSF-primed group (70±4% and 89±4%, respectively) than in the unprimed group (p<0.05).
Incubation of neutrophils with 100 µM LY294002 lead to an inhibition of the GM-CSF-primed ROS production of 93 ± 3%, which was statistically similar to the unprimed group. An important downstream target of PI3K is PKB/Akt. 37;38 As shown in Figure 5B (upper panel), fMLP induced PKB/Akt serine phosphorylation in a time dependent manner. Phosphorylation was maximal within 2 minutes and declined to near basal levels after 10 minutes of stimulation. GM-CSF alone stimulated PKB/Akt phosphorylation to a much lower extent ( Figure 5B ). Longer exposure demonstrated that GM-CSF-stimulated phosphorylation occurred with a maximum at 2 minutes ( Figure 5C ). Interestingly, PKB/Akt phosphorylation by fMLP could be enhanced by pretreatment of the neutrophils with GM-CSF. Figure 5D demonstrates that the phosphorylation of PKB/Akt by stimulation of unprimed or GM-CSF-primed neutrophils with fMLP, or GM-CSF alone, could be partially inhibited by preincubation of the neutrophils with 1 µM LY294002 and completely with 10 µM. This indicates that the concentrations LY294002 used effectively inhibited PI3K activation. Our results demonstrate that fMLP stimulation of neutrophils leads to the production of reactive oxygen species at least partially by activating PI3K, and they imply that the priming effect of GM-CSF on the fMLP-induced neutrophil burst is completely dependent on activation of PI3K. 
GM-CSF-mediated enhancement of fMLP-stimulated respiratory burst is inhibited by preincubation of healthy neutrophils with the ERK inhibitor, U0126
Next, we studied the role of the MEK/ERK-pathway in the fMLP-induced respiratory burst in neutrophils by using the extremely potent, selective inhibitor of MEK1/2, U0126. Figure 6A shows that the unprimed fMLP-stimulated ROS production was not significantly reduced by preincubation of the neutrophils with U0126 (39 ± 20%; p=0.554). However, GM-CSF priming of the respiratory burst could be significantly inhibited by 10 µM U0126 by 65 ± 1% (p=0.021). Similar results were obtained when neutrophils were preincubated with 50 µM PD98059, another chemical MEK1/2 inhibitor (data not shown).
We subsequently examined the activation of the MEK/ERK pathway at the protein level. Phosphorylation of Thr202/Tyr204 of ERK1/2 was observed within 30 seconds of fMLP stimulation ( Figure 6B ). GM-CSF stimulation alone lead to ERK1/2 phosphorylation with a maximum at 2 minutes, although at a much lower level than the fMLP-stimulated ERK1/2 phosphorylation. Priming of neutrophils with GM-CSF, followed by fMLP stimulation resulted in an enhanced ERK1/2 phosphorylation compared to the effects of either fMLP or GM-CSF alone. The MEK1/2 inhibitor U0126, when added at a concentration of 10 µM, was capable of completely inhibiting ERK1/2 phosphorylation in unprimed and GM-CSF-primed neutrophils stimulated with 1 µM fMLP, and in neutrophils stimulated with 5 ng/ml GM-CSF alone ( Figure 6C ). Together these data suggest that the MEK-ERK route is not involved in the unprimed ROS production, but that it does play a role in the GM-CSF-priming effect of the respiratory burst.
To establish the place of ERK in the signal transduction cascade, neutrophils were preincubated with LY294002 before fMLP or GM-CSF stimulation. As shown in Figure 7 , ERK1/2 activation by fMLP with or without GM-CSF priming was not inhibited by preincubation of the cells with increasing concentrations LY294002. In contrast, the ERK1/2 activation induced by GM-CSF stimulation alone was completely inhibited at 10 µM LY294002. These results indicate that whereas GM-CSF-mediated ERK1/2 phosphorylation is a downstream event of PI3K activation, the fMLP stimulated ERK1/2 phosphorylation in GM-CSF-primed cells is PI3K independent. Neutrophils from a healthy volunteer were preincubated with the indicated concentrations LY294002 for 30 minutes. Neutrophils were subsequently stimulated for two minutes with 1 µM fMLP alone, fMLP following priming of the neutrophils with 5 ng/mL GM-CSF, or 5 ng/mL GM-CSF alone. Stimulation was stopped by the addition of 1 X Laemmli buffer to the pelleted neutrophils and boiling the samples. Proteins were separated by SDS-PAGE, and Western blotting was performed using an antibody against phosphorylated ERK1/2 (upper panel). Lysates of unstimulated cells were run as negative controls (C). Equal loading was demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels).
Altered PI3K p110 protein levels and decreased PKB/Akt phosphorylation in neutrophils from MDS patients
Because our results indicate an involvement of PI3K in the priming of the respiratory burst and a disturbed priming of this burst in neutrophils from MDS patients, we investigated the protein levels of the PI3K subunit p110 in neutrophils from healthy donors (n=5) and MDS patients (n=7). Figure 8 shows that though the p110 levels differed between individual donors (Figure 8A ), the amount of p110 present in the neutrophil lysates of MDS patients was significantly higher then in healthy volunteers after correction for ERK levels ( Figure 8B, p<0.05) . These results indicate increased protein expression of the catalytically active p110 subunit in MDS neutrophils, possibly resulting in a disturbed regulation of the PI3K signalling pathway.
We subsequently examined the activation of PKB/Akt in neutrophils from MDS patients (n = 5). Isolated neutrophils were stimulated with fMLP with or without GM-CSF pretreatment or GM-CSF alone, and proteins were separated by SDS-PAGE. In each experiment, lysates of neutrophils from healthy controls, stimulated under the same experimental conditions, were run as controls. Time curve experiments in neutrophils from MDS patients demonstrated maximal PKB/Akt phosphorylation after 30 seconds of fMLP stimulation and after 2 min of Figure 8 . Increased PI3-kinase subunit p110 protein levels in neutrophils from MDS patients. (A) Neutrophils from healthy donors (n=5) and MDS patients (n=7) were resuspended in 1 X Laemmli buffer, and samples were boiled. Proteins were separated by SDS-PAGE, and Western blotting was performed using an antibody against PI3-kinase p110 (upper panels). Equal loading was demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels). (B) Protein levels were quantified by densitometry of the films. The p110 protein levels were corrected for ERK levels, and differences between the means of the normalised values were calculated between MDS neutrophils and healthy donors using the Student t test for unpaired samples. Significant differences are indicated with an asterisk (P < 0.05).
GM-CSF stimulation in most patients (Figure 9A-C) . As in healthy donors, GM-CSF priming of the neutrophils from the MDS patients resulted in an enhanced phosphorylation of PKB/Akt compared with the effects of fMLP or GM-CSF alone. Interestingly, in all cases studied, the total amount of phosphorylated PKB/Akt present after stimulation with fMLP with or without priming appeared lower in MDS neutrophils than in healthy controls (compare lanes 3 and 9 and lanes 6 and 10 in Figure 9A and lanes 3 and 11 and lanes 6 and 12 in Figure 9B-C) . Quantification of the phosphorylation levels by densitometry indicated that the amount of phosphorylated PKB/Akt present in fMLP-stimulated neutrophil lysates was significantly higher in healthy donors than in MDS patients (p<0.05). In GM-CSF-primed cells, fMLP stimulation also lead to a higher phosphorylation of PKB/Akt in healthy donors than in MDS patients, though this was not significant, because of the high SEM (p=0.073) ( Figure 9D ). Furthermore, a difference in the kinetics of phosphorylation was noted between MDS neutrophils and healthy controls. In 4 of 5 patients studied, the amount of fMLP-induced phosphorylation of PKB/Akt following GM-CSF priming was identical at 30 seconds and 2 minutes of stimulation, whereas in the majority of healthy controls the phosphorylation level was significantly higher at 2 minutes than at 30 seconds ( Figure 5B and data not shown). Protein loading was equal in all samples, as assessed by Western blotting for ERK1/2. These data indicate that in neutrophils from MDS patients, the kinetics and the maximal levels of PKB/Akt phosphorylation induced by fMLP stimulation and GM-CSF priming are affected.
Phosphorylation of ERK1/2 is decreased in neutrophils from MDS patients
Since we demonstrated that the MEK/ERK pathway is also involved in the GM-CSF-mediated priming of the respiratory burst, we compared the phosphorylation pattern of ERK1/2 after stimulation in neutrophils from healthy volunteers and MDS patients. FMLP-induced phosphorylation in MDS neutrophils could be enhanced by GM-CSF pretreatment in a manner similar to that in neutrophils from healthy controls ( Figure 9A-C, middle panels) . In all cases it was observed that the total amount of phosphorylated ERK1/2 present after 2 minutes of fMLP stimulation was slightly, but significantly, higher in GM-CSF-primed and unprimed neutrophils from healthy donors than in those from MDS patients (p=0.013 and 0.010, respectively), though this was much less pronounced than for phosphorylated PKB/Akt ( Figure 9D) .
Finally, to exclude the possibility that the GM-CSF receptor in MDS is defective in general, we examined the capability of GM-CSF to induce the tyrosine phosphorylation of STAT5. Figure 10 shows that the GM-CSF-induced STAT5 phosphorylation, though varying slightly between persons, did not differ significantly between MDS patients and healthy subjects. These data suggest that GM-CSF receptors on neutrophils from MDS patients are functional. Figure 9 . Phosphorylation of PKB/AKT and ERK1/2 in response to fMLP and GM-CSF is decreased in MDS patients. Neutrophils were isolated from whole blood from MDS patients and healthy controls as described.
Cells were stimulated with 1 µM fMLP with or without priming with 5 ng/mL GM-CSF, or 5 ng/mL GM-CSF alone for the indicated time. Stimulation of the neutrophils was stopped by the boiling samples in 1 X Laemmli buffer. The proteins were separated by SDS-PAGE, and PKB/Akt activation was detected by Western blotting, using antibodies against phosphorylated PKB/Akt (A-C, upper panels). The same blots were reprobed with an antibody against phosphorylated ERK1/2 (A-C, middle panels). ERK1/2 is shown in the lower panels and represents equal protein loading. The experiment was performed for 5 individual MDS patients and healthy controls. One patient was tested twice independently, with identical results. results of 3 representative experiments are shown (A-C). (D) Phosphorylation of PKB/Akt and ERK1/2 was quantified by densitometry of the films. The level of phosphorylation of PKB/Akt and ERK1/2 in neutrophil lysates from healthy donors was expressed as a percentage of the phosphorylation observed in cell lysates from MDS patients, run on the same gel. Significant differences are indicated with asterisks (P < 0.05).
Discussion
The present study demonstrates that the responses of neutrophils from MDS patients are significantly disturbed with regard to GM-CSF and G-CSF priming of the ROS production, whereas the fMLP-mediated cellular effects are not affected. In contrast to our findings, Carulli et al demonstrated a defect in the Factin polymerisation in neutrophils from MDS patients, but that applied especially to patients with refractory anemia (RA) with excess blasts (RAEB), REAB in transformation (RAEB-t) and chronic myelomonocytic leukaemia (CMML) 2 . In the present study, with patients with RA and RA with ring sideroblasts (RARS), no significant decrease in actin polymerisation was observed, though in 3 out of 8 patients a neutrophil subpopulation was observed that did not polymerise F-actin in response to fMLP. However, respiratory burst measurements in these patients did not reveal separate neutrophil subpopulations; all neutrophils were capable of producing H 2 O 2 following fMLP stimulation, indicating that the lack of F-actin polymerisation can not be attributed to an fMLP receptor defect. These results were further supported by our finding that Rac2 activation after fMLP stimulation was normal in neutrophils from MDS patients. In contrast, the priming effects of GM-CSF and G-CSF on ROS production were severely disturbed in neutrophils from MDS patients. Previous studies by Zabernigg et al 3 41 . Recently, it has been described that PI3K binds and activates the NADPH complex, including p40 phox and p47 phox , suggesting that it plays a major role in the respiratory burst 28;29 . This is confirmed by our finding that the PI3K inhibitor LY294002 is capable of inhibiting fMLP-stimulated ROS production in unprimed and GM-CSF primed neutrophils. To what extent the PI3K downstream target PKB/Akt is involved in the activation of the NADPH complex is unknown. Its involvement is often assumed as a result of the corresponding kinetics between PKB/Akt activation and respiratory burst as measured by cytochrome c reduction in response to chemoattractants 42 . Furthermore, as for ROS production, we show that the response of neutrophils to fMLP with regard to PKB/Akt phosphorylation can be primed by GM-CSF. fMLP-induced p47 phox phosphorylation has been shown to be mediated by ERK1/2 43 . However, the role of ERK1/2 in the chemoattractant-stimulated respiratory burst is disputed. Some studies indicate that MAPK is at least partially responsible for fMLP-induced ROS formation 30;43-45 , whereas in additional studies, no effect of ERK inhibitors on the neutrophil respiratory burst were observed 26;46 . The present study demonstrates that the fMLP-mediated ROS production is not significantly attenuated by the MEK inhibitor U0126. Moreover, it appeared that LY294002 at 1 and 10 µM significantly inhibited the fMLPtriggered respiratory burst without an effect on the fMLP-stimulated ERK1/2 phosphorylation in unprimed or GM-CSF-primed neutrophils, indicating a PI3K-independent activation of ERK. These data corroborate findings from Kodama et al who demonstrated that GM-CSF priming of ERK activity could not be inhibited by LY294002 46 . However, ROS formation in response to fMLP in GM-CSFprimed neutrophils was significantly inhibited by the MEK inhibitor U0126. These findings underscore the role of ERK in ROS production of primed granulocytes independent of the PI3K cascade and are in line with the recent findings of Hedin et al. They demonstrated that ERK activation by G i protein is regulated in part by a Ras-and PI3K-independent pathway which might be modulated by a tyrosine kinase 47 . One of signalling cascades that might be involved in this process is the GTPase Rap that can activate ERK independently of Ras 48 . Limited studies have been directed on the signalling events in hematopoietic cells of MDS patients. STAT5 DNA binding in response to erythropoietin (EPO) was shown to be impaired in cells of the erythroid lineage 49;50 . EPO exerts its STAT5-activating effect through phosphorylation of the Janus kinase 2 (JAK2) 51;52 , suggesting a central role for JAK2 in the disturbed signalling in MDS. However, GM-CSF stimulation of neutrophils from MDS patients led to STAT5 tyrosine phosphorylation that was comparable to healthy controls, implying that GM-CSF receptor and JAK2 activation is normal in MDS. In contrast, a significant defect was observed with regard to PKB/Akt and ERK1/2 phosphorylation. FMLP-stimulated PKB/Akt phosphorylation in unprimed and GM-CSF-primed neutrophils was drastically lowered in MDS patients. Moreover, the kinetics of PKB/Akt phosphorylation were different than they were in healthy controls. These findings might be related to the altered p110 protein levels found in MDS neutrophils. The abundance of the catalytically active PI3K subunit, p110 might result in a disturbed activation of the PI3K pathway. A recent study suggests that overexpression of myr-p110 in murine fibroblasts, resulting in constitutive PI3K activation, does not lead to constitutive PKB/Akt activation but rather to a reduced ability of stimuli to induce phosphorylation of PKB 53 .
Differences similar to those for PKB/Akt activation were observed for ERK1/2 phosphorylation, albeit to a lesser extent. Because the fMLP-mediated cellular responses were normal in MDS patients and GM-CSF could properly stimulate STAT5 activation, it is tempting to speculate that the convergence of fMLP and GM-CSF signalling is disturbed in MDS patients. It is conceivable that altered PI3K-PKB/Akt and ERK1/2 activation patterns found in MDS patients might lead to decreased priming of the respiratory burst by preventing proper assembly of the NADPH enzyme complex.
In conclusion, our studies indicate that PI3-kinase p110 protein levels are increased in neutrophils from MDS patients and that the phosphorylation of PKB/Akt and, to a lesser extent, ERK1/2 is disturbed in neutrophils from these patients. Further research will have to elucidate to what extent these alterations in signalling events are responsible for the disturbed neutrophil effector functions in MDS.
